Tag: Celgene
US: Celgene backs out of a $55m antitrust settlement
In an unusual move, Celgene has backed out of a $55 million settlement with patients and payers over allegations it illegally blocked competition to...
US: Amgen to buy Celgene psoriasis drug Otezla for $13.4B
According to the Financial Times, Amgen will buy Celgene’s psoriasis drug Otezla for US$13.4 billion in cash, clearing the way for Bristol-Myers Squibb to...
US: Bristol-Myers to buy Celgene in a US$74B deal
Bristol-Myers Squibb announced on Thursday, January 3, it would buy Celgene for about US$74 billion, combining two of the world’s largest cancer drug businesses...
Canada: Celgene, Pfizer, and Sanofi investigated by regulator
The Canadian Competition Bureau announced last month that it is closing an investigation into allegations of abuse of dominance by certain brand name drug...
US: Bristol-Myers and Celgene in US$74B pharmaceutical merger
Bristol-Myers Squibb is buying rival Celgene in a cash and stock deal valued at about US$74 billion or US$90 billion including debt.
The tie-up, which...
US: Celgene’s Juno Therapeutics for US$9B buy cleared clears HRS wait...
Celgene Corporation announced on Thursday, February 22, that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with respect to...
